Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Samsung Biologics Co.,Ltd.    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
SummaryChartsNewsRatingsCompanyConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

S.Korea shares rise on hopes of Fed's policy support; rising virus cases weigh

11/18/2020 | 02:05am EST

* KOSPI rises, foreigners net buyers for 10th session

* Korean won strengthens against U.S. dollar

* South Korea benchmark bond yield falls

* For the midday report, please click

SEOUL, Nov 18 (Reuters) - Round-up of South Korean financial markets:

** South Korean shares rose on Wednesday as investors focused on hopes of additional stimulus from the U.S. Federal Reserve, but worries about rising COVID-19 cases globally and tougher coronavirus-related curbs at home capped gains. The won gained, while the benchmark bond yield fell.

** KOSPI closed up 6.49 points, or 0.26%, at 2,545.64, reversing a 0.15% decline in the previous session.

** Fed Chairman Jerome Powell said on Tuesday the economy would continue to need both fiscal and monetary policy support, adding its commitment to using all tools to support recovery.

** South Korea reported 313 new daily COVID-19 cases, the highest since August, prompting authorities to tighten social distancing rules.

** Shares of Samsung BioLogics Co Ltd jumped 4.91% after the company said on Tuesday it is mass-producing a COVID-19 antibody treatment developed by Eli Lilly and Co , as the United States began distributing the drug last week after emergency-use approval.

** Hyundai Motor Co shares slid 1.64% as the company is being sued over a string of battery fires in its electric vehicles.

** Foreigners were net buyers for the tenth straight session, their longest buying spree since September 2019, purchasing a total net 5.2 trillion won ($4.71 billion) worth of shares on the main board.

** "Given KOSPI's recent and rapid rally, adjustments would be made for some time being," said Hana Financial Investment analyst Lee Jae-sun.

** The won ended at 1,103.8 per dollar on the onshore settlement platform, 0.25% higher than its previous close at 1,106.6.

** In offshore trading, the won was quoted at 1,103.2, while in non-deliverable forward trading its one-month contract was quoted at 1,103.3.

** The most liquid 3-year Korean treasury bond yield fell by 0.9 basis points to 0.951%.

($1 = 1,103.1800 won) (Reporting by Joori Roh, Additional reporting by Jihoon Lee; Editing by Rashmi Aich)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 2.19% 190.77 Delayed Quote.12.99%
HANA FINANCIAL GROUP INC. 0.00% 38150 End-of-day quote.10.58%
HYUNDAI CORPORATION -3.77% 16600 End-of-day quote.4.08%
HYUNDAI MOTOR COMPANY 0.42% 241000 End-of-day quote.25.52%
KOSPI COMPOSITE INDEX -2.13% 3027.9 Real-time Quote.7.78%
LG CHEM, LTD. -1.53% 964000 End-of-day quote.16.99%
SAMSUNG BIOLOGICS CO.,LTD. -1.99% 788000 End-of-day quote.-4.60%
SAMSUNG ELECTRONICS CO., LTD. -3.41% 85000 End-of-day quote.4.94%
All news about SAMSUNG BIOLOGICS CO.,LTD.
02:27aSamsung Elec's worst fall in 5 mths pulls down KOSPI after group leader's pri..
RE
01/16Samsung's Jay Y. Lee on cusp of stepping out of father's shadow
RE
01/08MARKET CHATTER : Combined Market Cap of Top South Korean Firms Hits $1.6 Trillio..
MT
2020S.Korea shares end at record high on biopharmaceuticals boost
RE
2020MARKET CHATTER : John Rim is the New CEO of Samsung Biologics
MT
2020Samsung Biologics, AstraZeneca Ceases Leukemia Drug Development; JV Likely to..
MT
2020Seoul Stocks Decline as Investors Opt for Profit-Booking at the End of Novemb..
MT
2020MARKET CHATTER : Major Samsung Units' Shares Make Double-Digit Jump After Chairm..
MT
2020MARKET CHATTER : South Korea to Raise Bio-Health Industry Investments to $9 Bill..
MT
2020MARKET CHATTER : Samsung Biologics, Celltrion to Build Fourth Plants at Songdo B..
MT
More news
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | A207940 | KR7207940008 | MarketScreener
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 788 000,00 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
NameTitle
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Ho-Yeol Yoon Managing Director & Head-Operations Support
James J. Choi Managing Director & Head-Information Technology
Yong-Ho An Managing Director & Head-Process Technology
Sector and Competitors
1st jan.Capitalization (M$)
SAMSUNG BIOLOGICS CO.,LTD.-4.60%48 243
CSL LIMITED-5.54%93 853
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-4.50%35 533
ALEXION PHARMACEUTICALS, INC.0.29%34 293
CELLTRION HEALTHCARE CO LTD--.--%19 919